Meeting
2011 ASCO Annual Meeting
A phase I dose-escalation study of ABT-888 (veliparib) in combination with carboplatin in HER2-negative metastatic breast cancer (MBC).
Authors
S. Viswanathan
James Cancer Institute and Solove Research Institute, Columbus, OH
S. Viswanathan , R. Wesolowski , R. M. Layman , G. Alejandra , B. Miller , J. J. Chalmers , S. Bejastani , W. Zhao , G. Pierluigu , J. Cotrill , M. A. Phelps , L. J. Schaaf , S. M. Geyer , N. Hall , M. V. Knopp , C. L. Shapiro , M. A. Villalona-Calero , A. Chen , M. R. Grever , B. Ramaswamy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
ER+
Clinical Trial Registration Number
NCT01251874
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS106)
Abstract #
TPS106
Poster Bd #
36H
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
NCI 8609: Interim fluoro-3’-deoxythymidine (FLT) PET imaging findings from the phase I trial of PARP inhibitor veliparib (V) and carboplatin (C) in advanced breast cancer.
First Author: Bhuvaneswari Ramaswamy
Poster
2013 ASCO Annual Meeting
Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer.
First Author: George Somlo
Poster
2018 ASCO Annual Meeting
A phase I/II trial adding poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel (Carbo-Tax) in patients with head and neck squamous cell carcinoma (HNSCC) Alliance A091101.
First Author: Michael J. Jelinek
Poster
2015 ASCO Annual Meeting
![Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with <i>BRCA1</i>- or <i>BRCA2</i>- (<i>BRCA</i>)-associated metastatic breast cancer (MBC).](https://d201v5jt9ylckg.cloudfront.net/156/10671/112102/112102_poster_pv.jpg)
Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).
First Author: George Somlo